(Q51760113)

11 April 2018

title

In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. (English)

1 reference

11 April 2018

2

George L Drusano

1 reference

11 April 2018

author name string

Paul G Ambrose

series ordinal

1

1 reference

11 April 2018

William A Craig

series ordinal

3

1 reference

11 April 2018

language of work or name

English

0 references

publication date

1 April 2012

1 reference

11 April 2018

Clinical Infectious Diseases

published in

1 reference

11 April 2018

volume

54 Suppl 3

1 reference

11 April 2018

page(s)

S220-8

1 reference

11 April 2018

Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Assessment of oritavancin serum protein binding across species

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-pheno

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Proinflammatory activity of a cecropin-like antibacterial peptide from Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS001

21 January 2018

Identifiers

DOI

10.1093/CID/CIS001

1 reference

11 April 2018

1 reference

11 April 2018